Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320120 | 0.86 | RECQL (0.62) | ALDH1A1RECQLGAALMNANPSR1 | |
| SCHEMBL4207867 | 0.73 | HDAC1 (0.57) | ALDH1A1GAALMNAHDAC1HDAC6 | |
| SCHEMBL1848202 | 0.71 | HDAC1 (0.52) | RECQLLMNAHDAC1HDAC6REN | |
| SCHEMBL14224515 | 0.70 | HDAC1 (0.58) | ALDH1A1GAALMNAHDAC1HDAC6 | |
| SCHEMBL5455537 | 0.70 | ALDH1A1 (0.69) | ALDH1A1GAALMNAKMT2AKDM4E | |
| SCHEMBL3900020 | 0.69 | HDAC1 (0.53) | ALDH1A1GAALMNAHDAC1HDAC6 | |
| SCHEMBL14197217 | 0.69 | HDAC1 (0.50) | LMNAHDAC1HDAC6RENKMT2A | |
| SCHEMBL18096180 | 0.69 | RECQL (0.43) | RECQLLMNAHDAC1HDAC6KMT2A | |
| SCHEMBL671194 | 0.68 | REN (0.55) | ALDH1A1GAALMNAHDAC1HDAC6 | |
| SCHEMBL21242365 | 0.68 | HDAC1 (0.59) | ALDH1A1GAAHDAC1HDAC6REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2023015156-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | HUDSPETH A JAMES (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | LATS1, LATS2, YAP1 | ALDH1A1 3828/4885RECQL 1306/4885GAA 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.